Covalon TechnologiesCOV
COV logo
Fair Value
CA$2.9
Share price15 Dec
CA$2.951.7% overvalued intrinsic discount
Loading
1Y22.92%
7D28.26%

Infection Prevention Demand And International Expansion Will Support Stronger Long Term Earnings

Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published
15 Dec 25
Views
25
Not Invested

Fair Value vs Share Price

CA$2.9
vs CA$2.951.7% overvalued intrinsic discount
PastFuture-9m44m2014201720202023202520262028Revenue CA$43.8mEarnings CA$4.9m
10.1%
Revenue growth
11.2%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Covalon Technologies

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

Flawless balance sheet with solid track record.

Market capCA$80.9m
PB2.6x
Estimated Growth8.1%
Dividend Yield5.1%
Full analysis

CEO & management

Brent Ashton
CEO
2.6yrs
CEO Tenure

Engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, the Middle East, Canada, Latin America, Asia, and internationally.